BONLUJAY
LIVE

Serial Number

98350784

Owner

Bristol-Myers Squibb Company

Attorney

Marilyn F. Kelly

Filing Date

Jan 10, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BONLUJAY Trademark

Serial Number: 98350784

BONLUJAY is a trademark filed by Bristol-Myers Squibb Company on January 10, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

January 10, 2024

Registration Date

Not Registered

Published for Opposition

April 29, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical and biological preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic agents, preparations and substances for medical purposes for human use; radiopharmaceutical imaging and detection agents for human use for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use for human use.

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 2, 2026 EXRA
SOU EXTENSION 2 GRANTED
Jun 2, 2026 EX2G
SOU EXTENSION 2 FILED
Jun 2, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 2, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 12, 2025 EXRA
SOU EXTENSION 1 GRANTED
Nov 12, 2025 EX1G
SOU EXTENSION 1 FILED
Nov 12, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 12, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 24, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 29, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 29, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 23, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 7, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 7, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 8, 2024 GNFN
FINAL REFUSAL E-MAILED
Dec 8, 2024 GNFR
FINAL REFUSAL WRITTEN
Dec 8, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 2, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 2, 2024 TROA
NOTICE OF REVIVAL - E-MAILED
Oct 2, 2024 NREV
PETITION TO REVIVE-GRANTED
Oct 2, 2024 PETG
TEAS PETITION TO REVIVE RECEIVED
Oct 2, 2024 PROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 1, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 1, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 1, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 27, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 29, 2024 NWOS
NEW APPLICATION ENTERED
Jan 10, 2024 NWAP